Project Grant R43DA063250
Award Date
5/1/25
Completion Date
4/30/26
Dollars Obligated
$398K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This federal Project Grant award of $275,253 from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports Epivario Inc.'s research to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The key products and services being delivered through this grant include: Epivario is screening next-generation inhibitors of the metabolic enzyme ACSS2, which has been shown to play a role in the encoding of...
This Project Grant award of $399,414 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to discover novel small molecule therapeutics for the safe and effective treatment of opioid use disorder (OUD). The awardee, Dark Matter Therapeutics, Inc., will leverage artificial intelligence (AI) to develop a drug discovery strategy that integrates target-based and phenotype-based methodologies. This approach seeks to identify...
This $716,226 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of novel small molecule allosteric modulators targeting the neurotensin receptor 1 (NTSR1) as a potential treatment for opioid use disorder (OUD). The overarching goals are to: 1) validate NTSR1 as a viable drug target for treating OUD, and 2) discover next-generation NTSR1 modulators with improved selectivity for...
This $858,600 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh. The grant aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex that could be targeted for developing new treatments for opioid use disorder (OUD). The research will use an unbiased transcriptomics approach to identify...
This $751,043 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research investigating the cellular and molecular mechanisms underlying the complex co-occurrence of opioid use disorder (OUD), major depressive disorder (MDD), and HIV in the human brain. The award will fund a comprehensive study using advanced multi-omics approaches, including single-nucleus RNA sequencing and single-nucleus ATAC...
This $715,238 federal Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a large-scale genome-wide association study (GWAS) of opioid-related traits in a diverse population of 500,000 individuals. The University of California, San Diego (UCSD) is the primary awardee and will work to uncover the genetic basis of the pre-addiction stages of opioid use, such as initial use, subjective response, and...
This $399,536 Project Grant was awarded by the National Institute on Drug Abuse (NIDA), a part of the National Institutes of Health (NIH), under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant supports research to design, synthesize, and test non-opioid drug candidates that can help combat the national opioid crisis, with a focus on reversing the effects of synthetic opioids like fentanyl. The key goals are to: 1) Develop and characterize chemical lead compounds and control...
This $159,711 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports a study titled "Electrophysiological Dynamics of Acute Opioid Use in Human Reward, Affect, and Pain Pathways." The project aims to investigate how acute opioid administration impacts neural connectivity within brain regions associated with opioid use disorder (OUD), including the amygdala, hippocampus, prefrontal cortex, and pain...
This $1,476,750 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a pilot randomized controlled trial to evaluate the use of the medication semaglutide as an adjunct treatment to buprenorphine for individuals with opioid use disorder (OUD). The study, to be conducted by Brigham & Women's Hospital Inc. over 2 years from September 2024 to August 2026, will assess semaglutide's impact on reducing...
This $197,748 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support research to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program to improve treatment outcomes for individuals with opioid use disorder (OUD), especially those using fentanyl. The key objectives of this 4-year project are to: 1) identify barriers to successful LDI completion through qualitative interviews, 2)...